Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies

Claus Bachert; Anju T. Peters; Enrico Heffler; Joseph K. Han; Heidi Olze; Oliver Pfaar; Chien Chia Chuang; Raj Rout; Richa Attre; Ledia Goga; Juby A. Jacob-Nara; Paul J. Rowe; Yamo Deniz; Zhen Chen; Siddhesh Kamat; Shahid Siddiqui

doi:10.1111/cea.14051

Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies

Claus Bachert^*, Anju T. Peters, Enrico Heffler, Joseph K. Han, Heidi Olze, Oliver Pfaar, Chien Chia Chuang, Raj Rout, Richa Attre, Ledia Goga, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Zhen Chen, Siddhesh Kamat, Shahid Siddiqui

^*Corresponding author for this work

Medicine, Allergy Division

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	244-249
Number of pages	6
Journal	Clinical and Experimental Allergy
Volume	52
Issue number	2
DOIs	https://doi.org/10.1111/cea.14051
State	Published - Feb 2022

Funding

Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52). Medical writing/editorial assistance provided by Joseph Hodgson, PhD, of Adelphi Group, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02912468 (SINUS‐24) and NCT02898454 (SINUS‐52). Medical writing/editorial assistance provided by Joseph Hodgson, PhD, of Adelphi Group, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1111/cea.14051

Cite this

Bachert, C., Peters, A. T., Heffler, E., Han, J. K., Olze, H., Pfaar, O., Chuang, C. C., Rout, R., Attre, R., Goga, L., Jacob-Nara, J. A., Rowe, P. J., Deniz, Y., Chen, Z., Kamat, S., & Siddiqui, S. (2022). Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. Clinical and Experimental Allergy, 52(2), 244-249. https://doi.org/10.1111/cea.14051

Bachert, Claus ; Peters, Anju T. ; Heffler, Enrico et al. / Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. In: Clinical and Experimental Allergy. 2022 ; Vol. 52, No. 2. pp. 244-249.

@article{eacad8a5600144ec9f9741072414116c,

title = "Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies",

author = "Claus Bachert and Peters, {Anju T.} and Enrico Heffler and Han, {Joseph K.} and Heidi Olze and Oliver Pfaar and Chuang, {Chien Chia} and Raj Rout and Richa Attre and Ledia Goga and Jacob-Nara, {Juby A.} and Rowe, {Paul J.} and Yamo Deniz and Zhen Chen and Siddhesh Kamat and Shahid Siddiqui",

note = "Funding Information: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52). Medical writing/editorial assistance provided by Joseph Hodgson, PhD, of Adelphi Group, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Funding Information: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02912468 (SINUS‐24) and NCT02898454 (SINUS‐52). Medical writing/editorial assistance provided by Joseph Hodgson, PhD, of Adelphi Group, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. ",

year = "2022",

month = feb,

doi = "10.1111/cea.14051",

language = "English (US)",

volume = "52",

pages = "244--249",

journal = "Clinical and Experimental Allergy",

issn = "0954-7894",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

Bachert, C, Peters, AT, Heffler, E, Han, JK, Olze, H, Pfaar, O, Chuang, CC, Rout, R, Attre, R, Goga, L, Jacob-Nara, JA, Rowe, PJ, Deniz, Y, Chen, Z, Kamat, S & Siddiqui, S 2022, 'Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies', Clinical and Experimental Allergy, vol. 52, no. 2, pp. 244-249. https://doi.org/10.1111/cea.14051

Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. / Bachert, Claus; Peters, Anju T.; Heffler, Enrico et al.
In: Clinical and Experimental Allergy, Vol. 52, No. 2, 02.2022, p. 244-249.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies

AU - Bachert, Claus

AU - Peters, Anju T.

AU - Heffler, Enrico

AU - Han, Joseph K.

AU - Olze, Heidi

AU - Pfaar, Oliver

AU - Chuang, Chien Chia

AU - Rout, Raj

AU - Attre, Richa

AU - Goga, Ledia

AU - Jacob-Nara, Juby A.

AU - Rowe, Paul J.

AU - Deniz, Yamo

AU - Chen, Zhen

AU - Kamat, Siddhesh

AU - Siddiqui, Shahid

N1 - Funding Information: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52). Medical writing/editorial assistance provided by Joseph Hodgson, PhD, of Adelphi Group, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. Funding Information: Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02912468 (SINUS‐24) and NCT02898454 (SINUS‐52). Medical writing/editorial assistance provided by Joseph Hodgson, PhD, of Adelphi Group, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85123814785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123814785&partnerID=8YFLogxK

U2 - 10.1111/cea.14051

DO - 10.1111/cea.14051

M3 - Article

C2 - 35092110

AN - SCOPUS:85123814785

SN - 0954-7894

VL - 52

SP - 244

EP - 249

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

IS - 2

ER -

Bachert C, Peters AT, Heffler E, Han JK, Olze H, Pfaar O et al. Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies. Clinical and Experimental Allergy. 2022 Feb;52(2):244-249. doi: 10.1111/cea.14051

Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this